Early Cell Fate Decisions of Human Embryonic Stem Cells and Mouse Epiblast Stem Cells Are Controlled by the Same Signalling Pathways by Vallier, Ludovic et al.
Early Cell Fate Decisions of Human Embryonic Stem Cells
and Mouse Epiblast Stem Cells Are Controlled by the
Same Signalling Pathways
Ludovic Vallier
1*, Thomas Touboul
1,2, Zhenzhi Chng
1, Minodora Brimpari
1, Nicholas Hannan
1, Enrique
Millan
1¤a, Lucy E. Smithers
3¤b, Matthew Trotter
1, Peter Rugg-Gunn
4, Anne Weber
2, Roger A. Pedersen
1
1Department of Surgery and Laboratory for Regenerative Medicine, University of Cambridge, Cambridge, United Kingdom, 2Laboratoire de transfert de ge `nes dans le
foie: applications the ´rapeutiques, Equipe Mixte Inserm U804, Universite ´ Paris XI Ba ˆtiment Gregory Pincus, Le Kremlin Bice ˆtre, France, 3Wolfson Institute for Biomedical
Research, University College London, London, United Kingdom, 4Hospital for Sick Children, Toronto Medical Discovery Tower, Toronto, Ontario, Canada
Abstract
Human embryonic stem cells have unique value for regenerative medicine, as they are capable of differentiating into a
broad variety of cell types. Therefore, defining the signalling pathways that control early cell fate decisions of pluripotent
stem cells represents a major task. Moreover, modelling the early steps of embryonic development in vitro may provide the
best approach to produce cell types with native properties. Here, we analysed the function of key developmental growth
factors such as Activin, FGF and BMP in the control of early cell fate decisions of human pluripotent stem cells. This analysis
resulted in the development and validation of chemically defined culture conditions for achieving specification of human
embryonic stem cells into neuroectoderm, mesendoderm and into extra-embryonic tissues. Importantly, these defined
culture conditions are devoid of factors that could obscure analysis of developmental mechanisms or render the resulting
tissues incompatible with future clinical applications. Importantly, the growth factor roles defined using these culture
conditions similarly drove differentiation of mouse epiblast stem cells derived from post implantation embryos, thereby
reinforcing the hypothesis that epiblast stem cells share a common embryonic identity with human pluripotent stem cells.
Therefore the defined growth factor conditions described here represent an essential step toward the production of mature
cell types from pluripotent stem cells in conditions fully compatible with clinical use ant also provide a general approach for
modelling the early steps of mammalian embryonic development.
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Introduction
Human Embryonic Stem cells (hESCs) are pluripotent cells
cultured from embryos at the blastocyst stage [1]. Their
pluripotent status confers upon them the capacity to differentiate
into a wide variety of cell types. However, generating fully
functional cells from hESCs and achieving this goal using
clinically-compatible conditions remain major challenges owing
to the presence of undefined serum and cellular components in
standard culture media and differentiation protocols. Indeed,
widely-used methods are based on media formulations containing
unknown factors and animal derived products in addition to serum
such as Matrigel, and stroma cells [2,3]. While modelling the early
steps of embryonic development in vitro may provide the best
approach for generating differentiated cells with native properties,
devising protocols for differentiation of pluripotent stem cells is
largely an empirical task. The earliest cell fate decisions during
mammalian embryonic development are the specification of extra-
embryonic tissues, starting with the trophectoderm and the
primitive endoderm. Differentiation of definitive embryonic tissues
occurs later, at the gastrulation stage, with the specification of the
ectoderm, mesoderm and endoderm germ layers from which all the
adult tissues are derived. Here, we analysed the effect of key
developmental signalling pathways such as Activin/Nodal, FGF
and BMP4 on early cell fate decisions of hESCs using an approach
based on a fully chemically defined medium. This is resulted in the
definition of the function of each pathway in the specification of
extra-embryonic tissues and the primary germ layers. Based on
these results, we developed and validated chemically defined culture
conditions for achieving specification of hESCs into neuroectoderm
and mesendoderm and into extra-embryonic tissues. Importantly,
these culture conditions worked equally well to promote similar
differentiation of epiblast stem cells (EpiSCs) derived from post-
implantation mouse embryos [4,5], although their effectiveness on
mouse Embryonic Stem Cells (mESCs) was limited. Together, these
results show that pluripotent mammalian stem cells can be induced
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6082to undergo early cell fate decisions in chemically defined medium
supplemented with a minimal set of growth factors, thereby
providing a general approach for modelling the transition between
the pluripotent state and specification of the three germ layers
during mammalian gastrulation. Finally, these defined culture
conditions are devoid of animal products, thus they also represent a
major step toward the generation of fully functional cell types
compatible with future clinical applications.
Results
Approach used to identify growth factors driving
differentiation of hESCs into ectoderm, mesoderm and
endoderm in chemically defined medium
The function of Activin/Nodal, FGF, Wnt and BMP signalling
pathways in the differentiation of the primary germ layers is highly
conserved between amphibia [6], fish [7] and mammals [8].
Consequently, these growth factors appeared to be the best
candidates to drive differentiation of hESCs. Accordingly, we
undertook a systematic analysis of the effects of these four factors
on hESC differentiation into neuroectoderm and mesendoderm in
the absence of feeders cells, using a chemically defined medium
(CDM) [9]. CDM is devoid of serum and is supplemented with
insulin, transferrin and defined lipids to which was added either
serum albumin or Polyvinyl Alcohol (PVA). The effect of
inhibiting the Activin, FGF and PI-3-kinase signalling pathways
was analysed in these conditions using respectively SB431542 [10],
a pharmacological inhibitor of Activin/Nodal receptors, SU5402
[11], an inhibitor of FGF receptors, or LY294002 an inhibitor of
PI-3-Kinase [12]. Briefly, H9 and hSF-6 hESC lines grown in
CDM (containing bovine or human serum albumin) supplemented
with Activin (10 ng/ml) and FGF (12 ng/ml) were plated on
plastic dishes pre-coated with human fibronectin [13]. After
48 hours, Activin and FGF were replaced by other growth factors
and inhibitors for varying periods. Expression of the pluripotency
marker Oct-4, the pluripotency and neuroectoderm progenitor
marker Sox2, the mesoderm marker Brachyury, and the
endoderm marker Sox17 was analysed using immunostaining
after 7 or 10 days of treatment (Tables 1 and 2). This approach
enabled a rapid semiquantitative assessment of the combinational
options involving the four growth factor pathways.
BMP4 drives differentiation of hESCs into a mixture of
primitive endoderm and trophectoderm cells in
chemically defined conditions
Addition of BMP4 in CDM induced a rapid decrease in the
level of expression of Oct-4 and SSEA-3 while increasing the
expression of the differentiation marker SSEA-1 (Figure 1A)
confirming that in contrast to mESCs, hESCs are not maintained
as pluripotent cells by BMP4 signalling [14,15]. Further studies
including immuno-staining (Figure 1A), Real time PCR
(Figure 1B), and microarray (Figure 1C) analyses revealed that
Table 1. Identification of culture conditions for inducing neuroectoderm and mesendoderm differentiation in CDM-BSA.
Conditions CDM Pluripotency Neuro Meso Endo
0ct4 Sox2 Brachyury Sox17
0 L H VL VL
Activin 10 ng/ml+FGF 12 ng/ml (7 Days) HH 00
Activin 10 ng/ml+SU 10 mM (7 Days) HH LL
FGF 12 ng/ml+SB 10 mM (7 Days) 0H 00
SB 10 mM+SU 10 mM 00 00
BMP4 50 ng/ml (7 days) 00 00
Acti 10 ng/ml+BMP4 50 ng/ml (7 days) 00 00
0 (4 or 5 days)+BMP4 50 ng/ml (3 days) 00 00
0 (4 or 5 days)+Activin 30 ng/ml+FGF 12 ng/ml (3 days) HH LL
0 (4 or 5 days)+Activin 30 ng/ml+BIO 5 mM (3 days) LH 00
SB 10 mM+BIO 5 mM (7 days) 0H 00
0 (4 or 5 days)+Activin 30 ng/ml+SU 10 mM (3 days) LL LV L
BMP4 50 ng/ml+Activin 30 ng/ml (7 days) 00 00
SB 10 mM+BMP4 50 ng/ml+FGF2 12 ng/ml (7 days) 0L 00
SB 10 mM (5 days)+BMP4 50 ng/ml+Activin 30 ng/ml (3 days) 0H 00
SB 10 mM (5 days)+Acti 30 ng/ml (3 days) 0H 00
SB 10 mM (5 days)+Acti 30 ng/ml+FGF 12 ng/ml (3 days) 0H 00
SU 10 mM (3 days) Activin 30 ng/ml (4 days) HH LL
SU 10 mM (4 days) Activin 30 ng/ml (4 days) HH LL
SU 10 mM (5 days) Activin 30 ng/ml (4 days) LL LL
H9 hESCs were grown for different periods in CDM-BSA supplemented with different growth factors (Activin, FGF2 or BMP4) or chemical inhibitors [SB431542 (SB) for
Activin/Nodal, SU5402 (SU) for FGF or BIO for GSK3b/Wnt]. Then, immunostaining analyses were used to determine the fraction of cells expressing the pluripotency
marker Oct-4, the neuroectoderm marker Sox2, the mesoderm marker Brachyury, and the endoderm marker Sox17. The levels of marker-expressing cells were divided
into five arbitrary categories: 0 for absence of expression, Very Low (VL) for ,1% expressing cells, Low (L) for ,5% expressing cells, Moderate (M) for .10% expressing
cells, High (H) for .50% expressing cells. Indicated in blue are conditions allowing the generation of neuroectoderm (expressing Sox2) and in red those inducing
mesendoderm (cells expressing Brachyury or Sox17).
doi:10.1371/journal.pone.0006082.t001
hESCs Cell Fate Specification
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primitive endoderm markers including GATA4, GATA6, Sox7,
CoupTFII and trophectoderm markers H19, CDX2, Eomesoder-
min, Hand-1 and haCG (Figure 1A, 1B, 1C, 1D and data not
shown). FACS analysis revealed that 90% of the cells grown for 7
days under these culture conditions had lost expression of the
pluripotency markers Tra-1-60 and Oct-4 (Figure 1D), confirming
the efficacy of BMP4 in inducing differentiation of hESCs. In
addition, cells generated under these conditions did not express the
mesendoderm markers Sox17 and GSC or the neuroectoderm
marker Sox1 (data not shown). Importantly, immunostaining
analyses showed that cells expressing the trophectoderm marker
CDX2 did not co-express the primitive endoderm marker Sox7
(data not shown), indicating that these two cell types represent
distinguishable outcomes. These results demonstrate that activa-
tion of BMP signalling in CDM is sufficient to drive differentiation
of hESCs toward the two earliest extra-embryonic lineages that
form in mammalian development. These results differ from the
study by Xu and Thomson, which suggested that BMP4 drives
differentiation of hESCs into a homogenous population of
trophectoderm cells [15]. However, their experiments were
performed on Matrigel and in medium containing serum and
thus included undefined factors that could have interfered with the
primitive endoderm-inducing effect of BMP4. This difference
illustrates the importance of conducting cell fate studies in
chemically defined conditions, where the identities of differenti-
ation-inducing or inhibiting factors are known.
Inhibition of Activin/Nodal signalling in the presence of
FGF drives differentiation of hESCs into neuroectoderm
progenitors
Our assessment of the four signalling pathways also showed that
inhibition of Activin/Nodal signalling by the Alk4/5/7 inhibitor
SB431542 (10 mM) systematically resulted in the loss of pluripo-
tency markers including Oct-4, while expression of Sox2 was
maintained (Figure 2A, 2B and 2C), confirming that inhibition of
Activin signalling induces differentiation of hESCs toward
neuroectoderm [16]. The addition of FGF2 (12 ng/ml) or BIO
(5 mM), a GSK3b inhibitor that mimics Wnt activity [17], was not
sufficient to maintain expression of Oct4 or to induce expression of
the mesendoderm and endoderm markers Brachyury and Sox17 in
the absence of Activin/Nodal activity (data not shown). Thus in the
absence of Activin signalling, FGF and Wnt signalling could neither
maintain the pluripotent status of hESCs nor drive their
differentiation toward mesendoderm in these chemically defined
culture conditions. Additionally, cells expressing the endoderm
markers Sox17, FoxA2 and Alpha-Fetoprotein (aFP) were never
observed following treatment with SB431542 (Table 1 and
Figure 2A), confirming the importance of Activin/Nodal signalling
in the commitment of pluripotent stem cells toward definitive
endoderm [2,18]. Finally, a combination of SB431542 (10 mM) and
FGF2 (12 ng/ml) in CDM generated highly proliferative cells that
expressed the neuroectoderm markers Sox1, Sox2, Gbx2, Nestin
andNCam,butnotthepluripotencymarkersOct4,SSEA-3,Tra-1-
60 or Nanog (Figure 2A, 2B, 2C, and data not shown). FACS
analysis revealed that 95% of the cells grown for 7 days under these
latter culture conditions maintained the expression of Sox2 (also an
early neuroectoderm marker) and became positive for the pan-
neuronal marker NCAM, as compared to only 10% displaying
NCam in CDM supplemented with Activin and FGF (Figure 2C).
Importantly, FGF signalling was necessary for neuroectoderm
differentiation since addition of SU5402 in CDM supplemented
with SB431542 essentially blocked this process (data not shown).
Finally, when the Oct4(2)/Sox2(+) cells generated by a combina-
tion of SB431542 (10 mM) and FGF (12 ng/ml) treatment were
grown as embryoid bodies (EBs) in non-adherent conditions in
CDM for 15 days and then the EBs were returned to adherent
culture conditions for 10 additional days, they produced progeny
showing widespread expression of neuronal differentiation markers,
including Nestin, NCAM, GFAP, Glutamate, N-cadherin, bIIITu-
bulin, Neurofilament and Smi3 (Figure 2D). Together these results
demonstrate that inhibition of Activin/Nodal activity in the
presence of sustained FGF activity is sufficient to generate a
population of neuroectoderm progenitors.
A combination of Activin, BMP4 and FGF2 in a three step
protocol drives differentiation of hESCs into
mesendoderm
Another important outcome of the approach was to demon-
strate the effect of Activin on mesendoderm differentiation in
Table 2. Identification of culture conditions for inducing neuroectoderm and mesendoderm differentiation in CDM-PVA.
Conditions CDM-PVA Pluripotency Neuro Meso Endo
0ct4 Sox2 Brachyury Sox17
Activin 10 ng/ml+FGF 12 ng/ml (7 Days) HH 0 0
Activin 10 ng/ml+SU 10 (7 Days) HH L L
FGF 12 ng/ml+SB 10 (7 Days) 0H 0 0
SU 10 (3 days) Activin 30 ng/ml (4 days) HH L L
SU 10 (4 days) Activin 30 ng/ml (4 days) HH L L
SU 10 (5 days) Activin 30 ng/ml (4 days) H H VL VL
Activin 5 ng/ml+SU 10 (3 days) Activin 30 ng/ml (4 days) LL M M
Activin 5 ng/ml+SU 10 (3 days) Activin 100 ng/ml (4 days) LL L H
Activin 5 ng/ml+SU 10 (3 days) Activin 30 ng/ml+FGF 20 ng/ml+BMP4 10 ng/ml (4 days) VL VL H H
H9 hESCs were grown for different periods in CDM-PVA supplemented with different growth factors (Activin, FGF2 or BMP4) or chemical inhibitors SU5402 (SU) for FGF.
Then, immunostaining analyses were used to determine the fraction of cells expressing the pluripotency marker Oct-4, the neuroectoderm marker Sox2, the mesoderm
marker Brachyury, and the endoderm marker Sox17. The levels of marker-expressing cells were divided into five arbitrary categories: 0 for absence of expression, Very
Low (VL) for ,1% expressing cells, Low (L) for ,5% expressing cells, Moderate (M) for .10% expressing cells, High (H) for .50% expressing cells. Indicated in blue are
conditions allowing the generation of neuroectoderm (expressing Sox2) and in red those inducing mesendoderm (cells expressing Brachyury or Sox17).
doi:10.1371/journal.pone.0006082.t002
hESCs Cell Fate Specification
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e6082Figure 1. Generation of extra-embryonic tissues using BMP4. (A) Immunostaining analyses for the expression of pluripotency markers (Oct-4,
SSEA-3), primitive endoderm markers (SSEA-1, GATA4), and trophectoderm markers (CDX2, Eomes) by H9 cells grown for 7 days in CDM+BMP4 10 ng/
ml. Scale Bar 50 mM. (B) Dynamic expression of pluripotency markers (Oct-4, Nanog), trophectoderm markers (CDX2, Hand1), primitive endoderm
hESCs Cell Fate Specification
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several studies to be able to generate mesendoderm cells from
mouse and human ESCs [2,3]. We found that high doses of
Activin (30 or 100 ng/ml) in CDM maintained a predominant
population of cells expressing the pluripotency markers Oct-4 and
Nanog while also inducing the expression of the definitive
endoderm markers Sox17 and CXCR4 in some cells (Figure 3B
and data not shown), suggesting that Activin signalling is
permissive but not sufficient for differentiation of hESCs toward
the mesendoderm lineage. The insufficiency of Activin for
mesendoderm differentiation in CDM differs from its effect in
previously published approaches that used serum, stroma cells and
complex extra-cellular matrices, all of which contain unknown
factors capable of influencing growth factor induced differentia-
tion. In agreement with this interpretation, we found that a
combination of Activin, FGF2 and BMP4 signalling efficiently
induced mesendoderm differentiation using a three step protocol
(Figure 3A). In the first step, hESCs grown initially in
CDM+Activin+FGF2 were plated for 48 hours on fibronectin in
CDM-PVA medium containing Activin (10 ng/ml) and FGF2
(12 ng/ml). This first step allowed the hESC colonies to attach
properly, and as expected cells continued to express high levels of
Oct4 but not Brachyury or Sox17 (data not shown). In the second
step, SU5402 (10 mM) and a lower dose of Activin (5 ng/ml) were
added for three days. Addition of SU5402 reduced adhesion of the
hESC colonies, which began to form compact aggregates of cells
(Figure 3A) expressing Oct4 and low levels of Brachyury but not
Sox17 (data not shown). These observations suggest that SU5402
acts as a pre-differentiation step in which neuroectoderm
differentiation was prevented by the inhibition of FGF signalling
and by the presence of Activin. In the third step, a combination of
BMP4 (10 ng/ml), FGF2 (20 ng/ml) and Activin (30 or 100 ng/
ml) was added, leading to spreading and differentiation of the
colonies (Figure 3A). After 24 hours in these conditions, a majority
of cells expressed high levels of Brachyury, while Oct4 expression
declined further (data not shown). During the following three days,
the number of Sox17 expressing cells increased progressively,
while Brachyury or Oct4 expressing cells almost disappeared (data
not shown and Figure 3B). Q-PCR (Figure 3B) and immuno-
staining (Figure 3C) analyses showed that these cells expressed
markers of definitive endoderm including CXCR4, Goosecoid,
Mixl1, FoxA2, GATA4, GATA6, Vent-2, WNT3, and N-
Cadherin. Moreover, transcripts of Sox7, a gene specifically
expressed in extra-embryonic endoderm, were not detected in this
population of cells by Q-PCR (Figure 3B). These observations
were confirmed by microarray analyses showing that the gene
expression profile characteristic of hESCs (high Oct-4, Nanog,
Sox2, Cripto and Nodal, etc.) was replaced with a profile
characteristic of definitive endoderm (high Sox17, CXCR4,
FoxA2, GATA4 and GATA6, etc.) (Figure 3D) when hESCs
were subjected to this protocol. Taken together these findings
show that modulation of Activin, FGF and BMP signalling can
lead to differentiation of mesendoderm in chemically defined
conditions.
We further explored the mesodermal and endodermal compo-
sition of the cells induced to differentiate using this three step
protocol. FACS analysis revealed that the proportion of cells
expressing the definitive endoderm surface marker CXCR4 [2,18]
or PDGFaR, a surface marker expressed in mesendoderm and
mesoderm during in vitro differentiation of mouse ESCs [19],
depended on the dose of Activin added at the third step of the
protocol (Figure 3E). In the presence of a high dose of Activin
(100 ng/ml), 70% of the cells expressed CXCR4 while only 7%
expressed PDGFaR. On the other hand, in the absence of
exogenous Activin, only 55% of the cells became positive for
CXCR4 while 21% of the cells expressed PDGFaR. This
observation was confirmed by Q-PCR analyses showing that the
highest expression of definitive endoderm markers (Sox17, Mixl1,
GSC) was obtained with the highest dose of Activin (100 ng/ml).
On the other hand, inhibition of Activin signalling by SB431542
during the third step of the protocol abolished expression of
definitive endoderm markers and resulted in the highest level of
expression for the mesendoderm/mesoderm marker Brachyury
(Figure 3B). Higher doses of BMP4 (100 ng/ml) or FGF (100 ng/
ml) did not increase the expression of mesendoderm markers,
while inhibition of BMP signalling by Noggin in the presence of
Activin and FGF2 resulted in persistent expression of pluripotency
markers (Oct-4, Nanog) (Figure 3B). In addition, inhibition of FGF
signalling by SU5402 reduced cell proliferation without decreasing
expression of mesendoderm markers (Figure 3B and data not
shown). Taken together, these results demonstrate that BMP4
signalling acts as an inducer of mesendoderm differentiation
whereas the intensity of Activin signalling influenced the cell fate
choice between mesoderm and endoderm [18,20]. Finally, we
tested the capacity for further differentiation of these mesendo-
derm progenitors by using a medium containing Foetal Bovine
Serum (FBS). In these conditions endoderm and mesoderm cells
further differentiated into diverse cell types expressing liver
(Albumin, aFeto Protein, HNF4), gut (CDX2) and cardiac
markers (Atrial natriuretic factor (ANF), a Actin, a1 Channel)
markers (Figure 3F). Additionally, beating cells were often
observed in these culture conditions (data not shown). Together
these results confirm that the mesendoderm progenitors generated
with the three step protocol were capable of differentiating further
into more mature endodermal and mesodermal derivatives.
Finally, equivalent results using the three step protocol were
obtained with both of the hESC lines used in this study (H9 and
hSF-6) (data not shown), thereby demonstrating a robust approach
for driving differentiation of hESCs toward the mesendoderm
lineage in chemically defined conditions.
markers (Sox7, GATA6) and definitive endoderm markers (Sox17, GSC) during differentiation of hESCs. H9 cells were differentiated following the
protocol described above. Following the first day after plating, RNAs were extracted every day and expression of the denoted genes was analysed
using Q-PCR. Normalized expression is shown as the mean6SD from two informative experiments. (C) A microarray gene expression heat map to
compare human embryonic stem cells (ESC) grown in CDM and extra-embryonic cells generated in CDM (CDM) supplemented with BMP4 (BMP). For
each gene (row) the heat map colours sample gene expression in units of standard deviation from the mean across all samples (columns). Up-
regulation is coloured in shades of red and down-regulation in shades of blue according to the scale shown at the bottom of the heat map. (D)
Fraction of cells expressing the pluripotency markers Tra-1-60 and Oct-4 after growth in the presence of BMP4 for 7 days. H9 cells were grown in
CDM+BMP4 10 ng/ml, and then the fraction of cells expressing Oct-4, and Tra-1-60 was determined using FACS. H9 cells grown in CDM+Activin
10 ng/ml+FGF2 12 ng/ml were used as positive control. (E) Fraction of cells expressing CDX2 after extra-embryonic differentiation. H9 cells were
grown in CDM+BMP4 10 ng/ml for 7 days, and then the fraction of cells expressing CDX2 was determined using FACS. H9 cells grown in CDM+Activin
10 ng/ml+FGF2 12 ng/ml were used as negative control.
doi:10.1371/journal.pone.0006082.g001
hESCs Cell Fate Specification
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e6082Figure 2. Generation of neuroectoderm precursors by inhibiting Activin signalling in the presence of FGF2. (A) Immunostaining
analyses for the expression of a pluripotency marker (Oct-4), neuroectoderm markers (Sox2, Nestin, N-CAM) or mesendoderm markers (Brachyury,
Sox17, FoxA2, aFP) by H9 cells grown for 7 days in CDM+Activin 100 ng/ml or in CDM+SB431542 10 mM+FGF2 12 ng/ml. Scale Bar 50 mM. Note
hESCs Cell Fate Specification
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e6082The signalling pathways controlling differentiation of
hESCs are shared by mouse EpiSCs but not by mESCs
We and others recently derived pluripotent stem cells (EpiSCs)
from the epiblast of post-implantation mouse embryo [4,5]. These
novel pluripotent embryonic stem cells share many properties with
hESCs including their low efficiency of clonal propagation, their
dependence on Activin signalling to maintain their pluripotency,
and their capacity to differentiate into extra-embryonic tissues
including trophectoderm in response to BMP4 [4]. Consequently,
we analysed the efficiency of the chemically defined culture
conditions described above to induce differentiation of mEpiSCs
into neuroectoderm, extra-embryonic tissues, and mesendoderm.
Inhibition of Activin/Nodal signalling by SB431542 (10 mM)
systematically resulted in acute, widespread loss of pluripotency
markers including Oct-4 and Nanog, while increasing expression
of Sox2, Sox1, Gbx2, Six3, and Tuj1 (Figure 4A and 4B). This
suggests that similarly to hESCs, inhibition of Activin signalling
induces differentiation of mEpiSCs into neuroectoderm. As
compared to hESCs, induction of extra-embryonic differentiation
in EpiSCs by addition of BMP4 (10 ng/ml) in CDM in the
absence of Activin and FGF was less efficient. Indeed, loss of
pluripotent cell markers was observed only after 2 weeks of culture
in CDM+BMP4 as compared to 5 days for hESCs. However, the
effect of BMP4 on differentiation was strongly increased by adding
the Activin/Nodal receptor inhibitor SB431542. A combination of
BMP4 and SB431542 resulted in a rapid decrease in the
expression of Oct-4 and Nanog, while increasing the expression
of trophectoderm markers (Cdx2, Hand1, aCG, H19, Eomes) and
the expression of primitive endoderm markers (Gata4, Gata6,
Sox7) (Figure 4A and 4B) [4]. This confirms that similarly to
hESCs, BMP4 signalling drives differentiation of EpiSCs into
extra-embryonic tissues. However, these observations also suggest
that contrary to hESCs, the endogenous Activin/Nodal-like
signalling activity in EpiSCs is sufficient to block differentiation
of EpiSCs induced by exogenous BMP4. Finally, mEpiSCs were
subjected to the three step protocol for mesendoderm induction
developed for hESCs. This led to a pronounced decrease in
pluripotency markers (Oct-4 and Nanog) and an increase in
mesendoderm markers (Brachyury, Eomes, Mixl1, Sox17)
(Figure 4A and 4B). Taken together, these results show that
mEpiSCs can be induced to differentiate into neuroectoderm,
extra-embryonic tissues, and mesendoderm using similar chemi-
cally defined culture conditions as hESCs.
We then analysed the efficiency of these culture conditions for
driving differentiation of mESCs. All three culture conditions
tested (SB431542+FGF2; BMP4; three step protocol) induced
differentiation of mESCs, as shown by an abrupt decrease in their
Oct-4 expression (Figure 4C). However, these experiments were
performed in the absence of LIF and this condition alone was
sufficient to induce differentiation of mESCs grown in CDM
(Figure 4c). Furthermore, inhibition of Activin/Nodal signalling by
SB431542 did not increase mESC expression of the neuroecto-
derm markers Sox2 and Six3, and addition of BMP4 did not induce
a specific and significant increase in the expression of the
extraembryonic tissue markers GATA6 and CDX2 (Figure 4C).
Finally, when the three step protocol was applied to mESCs, there
was only a marginal increase in Brachyury and no concomitant
increase in Sox17 (Figure 4C), suggesting that mESCs were not able
to progress toward the definitive endoderm lineage under these
culture conditions. Importantly similar results were generated with
two different mESC line (CGR8 kind gift of Prof. Austin Smith, and
R1 kind gift of Prof. Andreas Nagy) confirming these observation
were independent of the cell line used. Taken together, these
observations show that the chemically defined growth factor
conditionscapableofdrivingdifferentiationofhESCsand mEpiSCs
were not similarly effective with mESCs. This implies that the
distinct embryonic origin or identity of different types of pluripotent
stem cells define their responsiveness to differentiation induction,
just as it does for maintenance of pluripotency. These results also
support the hypothesis that hESCs more closely resemble
pluripotent cells of post-implantation mouse embryos than
pluripotent cells of the inner cell mass, since hESCs and EpiSCs
react similarly to all the culture conditions tested here [4,5].
Discussion
hESCs and EpiSCs provide convergent in vitro systems
enabling the analysis of mechanisms controlling cell fate
decisions during early mammalian development
Taken together, our observations show that progenitors both for
embryonic and extra-embryonic tissues (primitive endoderm and
trophectoderm) resulting from the earliest cell fate decisions in
mammalian development can be generated in chemically defined
conditions from hESCs and EpiSCs. Moreover this can be
achieved by modulating the activities of a small number of specific
growth factors either through their addition to the medium or
their pharmacological inhibition (for summary see Figure 5). Our
systematic analysis clearly showed that inhibition of Activin/Nodal
signalling in the presence of FGF2 was sufficient to initiate
neuroectoderm specification by all the four types of pluripotent
stem cells in vitro. While the importance of FGF signalling in
neuroectoderm specification has been clearly established in chick
and amphibian embryos and in mESCs [21–24], the function of
Activin/Nodal in this cell fate choice in vertebrate embryogenesis
has only recently been described. Overexpression of Nodal in
hESCs blocks neuroectoderm differentiation of hESCs [25]
whereas overexpression of the Nodal inhibitor Lefty promotes
differentiation of hESCs toward neuroectoderm [16]. Interesting-
ly, genetic studies have shown that inhibition of Nodal is also
sufficient to induce neuroectoderm specification at a pre-
gastrulation stage in the mouse embryo [21–24,26]. Similarly,
inhibition of Activin/Nodal receptor-mediated signalling is
necessary for neural differentiation in Xenopus embryos [27].
These observations suggest that inhibition of Activin/Nodal
homogenous expression of both Oct-4 and Sox2 in Activin (Yellow staining), but only Sox2 in FGF+SB (Green Staining). (B) Dynamic expression of a
pluripotency marker (Oct-4) and neuroectoderm markers (Sox2, Sox1, Gbx2) during differentiation of hESCs. H9 cells were differentiated following the
protocol described above. Following the first day after plating, RNAs were extracted every 2 days and expression of the denoted genes was analysed
using Q-PCR. Normalized expression is shown as the mean6SD from two informative experiments. (C) Fraction of cells expressing the pluripotency
markers Oct-4, Tra-1-60 and Sox2 and the neuronal markers Sox2 and N-CAM after growth in the presence of SB431542 for 7 days. H9 cells were
grown in CDM+SB431542 10 mM+FGF2 12 ng/ml (SB+FGF), and then the fraction of cells expressing Oct-4, Sox2 and N-CAM was determined using
FACS. H9 cells grown in CDM+Activin 10 ng/ml+FGF2 12 ng/ml (Activin+FGF) were used as control. (D) Expression of neuronal markers by fully
differentiated neuroectoderm progenitors. H9 cells were induced to differentiate into neuroectoderm in CDM+SB431542 10 mM+FGF2 12 ng/ml. The
resulting neuroectoderm progenitors were then grown as embryoid bodies (EBs) in non-adherent conditions for 14 days to allow further
differentiation. The resulting EBs were then plated back on plastic and grown for 14 additional days before assessment. Nuclei are shown by Hoechst
staining. Scale Bar 100 mM.
doi:10.1371/journal.pone.0006082.g002
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e6082Figure 3. Generation of mesendoderm using a combination of Activin, FGF2 and BMP4. (A) Colony morphologies formed in response to
the three-step protocol to differentiate hESCs into mesendoderm progeny. H9 cells were grown for 2 days in CDM/PVA+Activin 10 ng/ml+FGF2
12 ng/ml, then for 72 hours in CDM/PVA+SU5402 10 mM+Activin 5 ng/ml. The next 4 days, cells were grown in CDM/PVA+Activin 30 ng/ml+FGF2
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e6082signalling is essential for induction of neuroectoderm not only in
vitro but also during gastrulation in vivo.
We also observed that addition of Noggin could improve
neuroectoderm differentiation of hESCs and mEpiSCs (data not
shown), suggesting that their endogenous BMP signalling interferes
with neuroectoderm specification. This result reinforces studies in
the mouse [28] and in amphibians [29] showing that BMP inhibits
early neuronal development and thus its inhibition in turn is
necessary for proper neuroectoderm specification. However in
hESCs and mEpiSCs, BMP signalling acts as a potent inducer of
extra-embryonic tissue differentiation (in the absence of high
Activin and of FGF) and of mesendoderm progenitors (in the
presence of Activin high dose and FGF). Thus, BMP signalling
acts in combination with other growth factors to induce
differentiation rather than to maintain pluripotency, as it does in
mESCs in combination with LIF [14]. A role for BMP4 in
mesendoderm specification has also been clearly demonstrated by
genetic studies in the mouse showing that absence of BMP
signalling arrests the development of embryos at the early
gastrulation stage [30–32]. Consistently with this, BMP4 in
combination with Activin and FGF is both necessary and sufficient
to drive differentiation of hESCs and mEpiSCs into mesendoderm
progenitors in vitro. BMP4 thereby appears to convert Activin/
Nodal signalling into a potent inducer of mesendoderm differen-
tiation, since when combined with Activin or with Activin+FGF2,
BMP4 is able to induce differentiation of hESCs in a fully
chemically defined medium. Finally, the importance of BMP4
signalling in the differentiation of extra-embryonic endoderm into
visceral endoderm has been clearly demonstrated in the mouse
[33,34]. However, an essential function of BMP in the earliest
stages of extraembryonic tissues specification remains intriguing
since this function has not been revealed through in vivo loss of
function studies [30–32]. Yet, those studies cannot exclude a
maternal effect or signalling through other receptors, and thus
further in vivo investigations are warranted to definitively exclude
such a role for BMP signalling in vivo. Taken together, these
observations show that Activin, BMP and FGF signalling play
pivotal functions in cell fate specification of pluripotent stem cells.
Moreover, the mechanisms controlled by these pathways mimic
those involved in the specification of the embryonic germ layers
during in vivo mammalian development. Accordingly, the growth
factor-driven cell fate choices methods of differentiation described
here provide an opportunity to study the molecular mechanisms
controlling cell fate specification of pluripotent cells equivalent to
early stages of human and mouse embryonic development.
To conclude, growing hESCs and mEpiSCs in chemically
defined conditions reveals an overarching similarity in their
responsiveness to growth factors that maintain pluripotency or
induce differentiation. The distinction between their shared
responses and those of mESCs to these same growth factors
underscores the development of pluripotency itself: pluripotent
phenotypes range from that of mESCs (derived from the inner cell
mass of the late blastocyst) to EpiSCs (derived from pre-
gastrulation stages) and hESCs. Our findings lead to the
conclusion that dependency on Activin/Nodal signalling itself
defines a stage of mammalian stem cell pluripotency regardless of
provenance. Therefore, the further investigation of the signalling
cascades responsible for pluripotency and differentiation of such
pluripotent stem cells will be valuable for understanding
mechanisms underlying their similarities, as well as for delivering
the clinical benefits of hESCs.
Materials and Methods
Growth of hESCs in feeder free and serum free conditions
For feeder and serum free culture, H9 (WiCell, Madison, WI)
and hSF-6 (UCSF, San Francisco, CA) hESCs were grown in
chemically defined medium (CDM) [9], supplemented with
Activin (10 ng/ml, RandD systems) and FGF2 (12 ng/ml, RandD
systems). The original composition of CDM was 50% IMDM
(Gibco) plus 50% F12 NUT-MIX (Gibco), supplemented with
7 mg/ml of insulin (Roche), 15 mg/ml of transferrin (Roche),
450 mM of monothioglycerol (Sigma) and 5 mg/ml bovine serum
albumin fraction V (Europabioproducts). For the humanised
version of CDM, BSA was replaced by human Serum Albumin
(Sigma) or Polyvinyl Alcohol (CDM-PVA) (Sigma). Every 4 days,
cells were harvested using 5 mg/ml collagenase IV (Gibco) and
then plated into dishes (Costar) that were pre-coated with 15 mg/
ml of human Fibronectin (Chemicon) for 20 minutes at 37uC and
then washed twice in PBS.
Differentiation of hESCs in chemically defined conditions
hESCs grown in feeder free and serum free conditions were
harvested using 5 mg/ml collagenase IV or Accutase then split
into plates pre-coated with fibronectin. hESCs were grown for the
first two days in CDM supplemented with Activin (10 ng/ml,
RandD systems) and FGF2 (12 ng/ml, RandD systems). To obtain
neuroectoderm progenitors, hESCs were grown in CDM or in
CDM-PVA in the presence of SB431542 (10 mM Tocris) and
FGF2 (12 ng/ml, RandD systems) for 7 additional days. The
resulting cells were grown in non-adherent conditions for 10 days
and then plated back for 5 additional days in CDM to obtain fully
differentiated neuronal cells. To obtain mesendoderm precursors,
hESCs were grown for the 3 following days in CDM-PVA in the
presence of SU5402 (10 mM, Calbiochem) and Activin (5 ng/ml,
RandD systems). Then, the resulting cells were grown for a further
20 ng/ml+BMP4 10 ng/ml. Images of the same colonies were captured every day for 9 days. Scale Bar 200 mM. (B) Effect of different combinations
and doses of Activin, FGF2 and BMP4 on the differentiation of hESCs grown in CDM/PVA. Following the third day in CDM/PVA+SU5402 10 mM, H9
cells were induced to differentiated in CDM/PVA supplemented with different combination of growth factors. RNAs were extracted after 3 days and
expression of the denoted genes was analysed using Q-PCR. Normalized expression is shown as the mean6SD from two informative experiments.
hESCs grown in CDM+Activin+FGF or differentiated in CDM+SB431542+FGF2 were used as negative controls. (C) Expression of specific markers for
mesendoderm in hESCs differentiated in CDM/PVA supplemented with Activin, FGF2 and BMP4 in the three step protocol. Nuclei are shown by
Hoechst staining. Scale Bar 100 mM. (D) Microarray gene expression heat map to compare human embryonic stem cells (ESC) grown in CDM
supplemented with Activin and FGF and mesendoderm cells generated in CDM/PVA supplemented with Activin, FGF and BMP4 (LE). Up-regulation is
coloured in shades of red and down-regulation in shades of blue according to the log z scale shown at the bottom of the heat map. Gene names
marked with an asterisk denote genes that pass a significant differential regulation threshold. (See Material and Methods). (E) Fraction of cells
expressing the definitive endoderm marker CXCR4 and the mesendoderm/mesoderm marker PDGFaR after induction of differentiation in CDM PVA
in the presence of increasing doses of Activin. H9 cells were differentiated following the three step protocol described above in the presence of
Activin (30 or 100 ng/ml). Fraction of cells expressing CXCR4 or PDGFaR was determined using FACS 8 days after plating. (F) RT-PCR analyses for the
expression of liver markers (Albumin, HNF4, aFP), gut marker (CDX2) and cardiac markers (ANF, a Actinin, a-1 Channel) in endoderm progenitors
grown in media containing serum. Endoderm progenitors generated using the three step protocol were differentiated in media containing three
different FBS lots. RNAs were extracted after 5 and 10 days of differentiation and the expression of genes expressed was analysed using RT-PCR.
doi:10.1371/journal.pone.0006082.g003
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PLoS ONE | www.plosone.org 9 June 2009 | Volume 4 | Issue 6 | e6082Figure 4. Contrary to mESCs, EpiSCs are responsive to culture conditions controlling differentiation of hESCs into extra-embryonic
tissues, neuroectoderm and mesendoderm. (A) Expression of pluripotency markers (Oct-4, Nanog) and neuroectoderm (Sox2, Sox1, Six3, Tuj1
and Gbx2), extra-embryonic markers (Cdx2, Hand1, Sox7, GATA6) and mesendoderm markers (Brachyury, Mixl1, Eomes, Sox17) during differentiation
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PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e60823 or 4 days in CDM-PVA in the presence of BMP4 (10 ng/ml,
RandD systems), FGF2 (20 ng/ml, RandD systems) and Activin
(30 ng/ml or 100 ng/ml, RandD systems).
Differentiation of mESCs in chemically defined conditions
R1 mESCs and CGR8 mESCs were grown on 60 mm plates
(Costar) pre-coated with 0.1% porcine gelatine (Sigma) and
containing 1610
5 irradiated mouse embryonic fibroblasts in
KSR medium containing 20% serum Replacer (Gibco) supple-
mented with LIF. Confluent cells were passaged using trypsin
(Gibco) and then transferred at low density (,1000 cells/well of a
6 well plate) on plastic plates (Costar) pre-coated with 0.1%
porcine gelatine (Sigma) and FBS (Hyclone). The resulting cells
were then grown in the culture conditions inductive for extra-
embryonic, neuroectoderm and mesendoderm differentiation as
described above.
of mouse EpiSCs using the culture conditions developed with hESCs. EpiSCs were differentiated following the conditions described above for hESCs
(SB+FGF for neuroectoderm, BMP4 for extra-embryonic tissues, three step protocol for mesendoderm). Following the ninth day after plating, RNAs
were extracted and expression of the denoted genes was analysed using Q-PCR. Normalized expression is shown as the mean6SD from two
informative experiments. (B) Expression of pluripotency markers (Oct-4, Nanog, SSEA-1), extra-embryonic markers (CDX2, Sox7, GATA4),
neuroectoderm markers (Sox1, Nestin, bIII tubulin) and mesendoderm markers (Brachyury and Sox17) in EpiSCs differentiated using the conditions
developed for hESCs. Expression of the genes denoted was analysed by immuno-fluoresence analyses. Nuclei are shown by Hoechst staining. Scale
Bar 100 mM. (C) Expression of pluripotency markers (Oct-4), extra-embryonic markers (CDX2, GATA6), neuroectoderm markers (Sox2, Six3) and
mesendoderm markers (Brachyury and Sox17) in mESCs differentiated using the method developed with hESCs. mESCs were differentiated in CDM as
described for hESCs and then the expression of the genes denoted was analysed by Real-Time PCR. Normalized expression is shown as the mean6SD
from three experiments.
doi:10.1371/journal.pone.0006082.g004
Figure 5. Cell signalling pathways controlling cell fate specification of pluripotent cells in vitro. A) Pluripotency of hESCs and mEpiSCs
relies on Activin signalling and to a lesser extent on FGF signalling to maintain their pluripotent status. BMP signalling inhibition may be required to
avoid extra-embryonic differentiation, depending on the level of endogenous BMP signalling activity of each cell type. B) Inhibition of Activin/Nodal
signalling induces differentiation toward neuroectoderm in the presence of FGF2. C) BMP4 induces differentiation toward extra-embryonic tissues
which is blocked by Activin and FGF2. D) BMP alternatively induces mesendoderm in cooperation with Activin (high dose) and FGF2. This model
summarises results from hESCs and mEpiSCs and distinguish them from mESCs which remain pluripotent in LIF+BMP.
doi:10.1371/journal.pone.0006082.g005
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For detection of N-CAM, CXCR4 and PDGFa Receptor,
adherent cells were washed twice in PBS and then incubated for
20 minutes at 37uC in Cell Dissociation Buffer (Invitrogen). Cells
were dissociated by gentle pipetting and resuspended at approx-
imately 0.1 to 1610
5 cells/ml in PBS+3% normal goat serum
containing 0.1% azide (NGS) (Serotec). Cells were incubated for
40 minutes at 4uC with FITC or PE conjugated antibody to
CXCR4 (1:50, Pharmingen), N-CAM (1:200, Pharmingen), or
PDGFaR (1:50, Pharmingen) or the corresponding isotype control
(mouse IgG isotype control, Pharmingen). Subsequently, cells were
resuspended in PBS+3% NGS for staining with 7-aminoactino-
mycin D (7-AAD) viability dye (Immunotech) at 20 ml/ml for 15
minutes at room temperature. Live cells identified by 7-AAD
exclusion were analyzed for surface-marker expression using
FACSCalibur or sorted using a Dakocytomation Mo Flo high
speed flowcytometer.
RNA extraction and Real time PCR
Total RNAs were extracted from hESCs or differentiated
progenitors using the RNeasy Mini Kit (Qiagen). Each sample was
treated with RNAse-Free DNAse (Qiagen) in order to avoid DNA
contamination. For each sample 0.6 mg of total RNA was reverse
transcribed using Superscript II Reverse Transcriptase (Invitro-
gen). Real time PCR reaction mixtures were prepared as described
(SensiMiX protocol Quantace) then denatured at 94uC for 5
minutes and cycled at 94uC for 30 seconds, 60uC for 30 seconds,
and 72uC for 30 seconds followed by final extension at 72uC for 10
minutes after completion of 40 cycles. Primer sequences were
described elsewhere[2,25]. Real time PCR reactions were
performed using a Stratagene Mx3005P in triplicate and
normalised to PBGD in the same run.
Microarray Methods
Sample RNA was hybridized to Affymetrix hg-u133+2 Gene-
Chips. All sample arrays were background corrected, normalized
and summarized using default parameters of the RMA model [35].
Array processing was performed using the affy package of the
Bioconductor (http://www.bioconductor.org) suite of software for the
R statistical programming language (http://www.r-project.org).
The resulting data set contained processed gene expression values
for 54675 probe-sets. All hybridizations employed are publicly
available in MIAME format from the ArrayExpress microarray
repository (European Bioinformatics Institute; http://www.ebi.ac.
uk/arrayexpress) with accession number E-MEXP-930. For the
Analysis of Differential Regulation, the moderated t-statistic of [36],
implemented in the Limma package of Bioconductor, was employed to
assess the significance of differential gene (probe-set) expression
between sample groups. In order to reduce errors associated with
multiple hypothesis testing on such a scale, the significance p-values
obtained were converted to corrected q-values using the FDR
method [37]. Probe-sets with associated q,0.01 (FDR 1%) were
deemed to exhibit significant differential expression between sample
groups. For data visualisation, the heat maps of gene expression
were created by importing relevant subsets of RMA processed
microarray gene expression data into the dChip v1.3 microarray
analysis package (http://www.biostat.harvard.edu/complab/
dchip/). In the case wherein a gene is represented by more than
one probe-set on the array, a single probe-set was chosen to
represent gene expression in the heat map according to highest
mean expression over all samples (i.e. the most reliable sample
hybridization regardless of group membership).
Immunofluorescence
HESCs or their differentiated progeny were fixed for 20 minutes
at 4uC in 4% paraformaldehyde (PFA) and then washed three times
in PBS. Cells were incubated for 20 minutes at room temperature in
PBS containing 10% donkey serum (Serotec) and subsequently
incubated overnight at 4uC with primary antibody diluted in 1%
donkey serum in PBS as follows: Oct-4 (1:100, Abcam ab18976 or
SantaCruz), Sox2 (1:100, Abcam ab15830), Brachyury (1:100,
Abcam ab20680 or RandD systems), Sox17 (RandD systems),
FoxA2 (1:50, Abcam ab5074), GATA4 (1:250, SantaCruz),
GATA6 (1:200, Abcam ab22600 or Santa Cruz), Vent-2 (1:100,
Abcam ab20913), Goosecoid (1:25, Abcam ab21059), Wnt3A
(1:100, Abcam ab19925), CXCR4 (1:100, RandD Systems or
Pharmingen). Nestin (1:200, Abcam ab5968), NCAM (1:100,
Abcam ab8077), GFAP (Abcam), Neurofilament (Abcam), bIII
Tubulin (Abcam), SMI31 (Covance), Glutamate (Sigma), N-
Cadherin (1:100, Abcam ab18203). Cells were then washed three
times in PBS and incubated with Texas Red or fluorescein-
Isothiocyanate-conjugated anti-mouse IgG (Sigma 1:200 in 1%
donkey serum in PBS) or rabbit IgG (Jackson laboratory 1:400 in
donkey serum in PBS) or Goat IgG (Jackson laboratory 1:400 in
donkey serum in PBS) for two hours at room temperature.
Unbound secondary antibody was removed by 3 washes in PBS.
Hoechst 33258 was added to the first wash (Sigma 1:10000).
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